A Phase I study of indoximod in patients with advanced malignancies

Oncotarget

Volumn 7, Issue 16, 2016, Pages 22928-22938

  Soliman, Hatem H ^a   Minton, Susan E ^a   Han, Hyo Sook ^a   Ismail Khan, Roohi ^a   Neuger, Anthony ^a   Khambati, Fatema ^a   Noyes, David ^a   Lush, Richard ^a   Chiappori, Alberto A ^a   Roberts, John D ^b   Link, Charles ^c   Vahanian, Nicholas N ^c   Mautino, Mario ^c   Streicher, Howard ^d   Sullivan, Daniel M ^a   Antonia, Scott J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NEWLINK GENETICS   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

1 methyl D tryptophan; Immunomodulator; Indoleamine 2,3 dioxygenase; Indoximod

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; INDOXIMOD; 1-METHYLTRYPTOPHAN; ANTINEOPLASTIC AGENT; INDOLEAMINE 2,3 DIOXYGENASE; TRYPTOPHAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLURRED VISION; BRAIN ISCHEMIA; CANCER FATIGUE; CLINICAL EFFECTIVENESS; CONFUSION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENCEPHALOMYELITIS; FATIGUE; FEMALE; FEVER; FRACTURE; HEADACHE; HIP PAIN; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHYSITIS; ILEUS; INSOMNIA; INTESTINE OBSTRUCTION; KNEE PAIN; LEG PAIN; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PROTEIN DETERMINATION; PROTEINURIA; PROTHROMBIN TIME; RASH; SENSORY NEUROPATHY; SHOULDER PAIN; SOLID TUMOR; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; VOMITING; WEAKNESS; WEIGHT REDUCTION; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TRYPTOPHAN; YOUNG ADULT;

EID: 84965054294     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8216     Document Type: Article

References (28)

1. Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, Gaubatz S, Zhang H, Prochownik E, Eilers M and Prendergast GC. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene. 1999; 18:3564-3573.
2. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U and Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:9689-9694.
3. Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C and Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. International journal of cancer. 2000; 85:376-383.
4. Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J and Prendergast GC. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. International journal of cancer. 2000; 86:155-161.
5. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E and Prendergast GC. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature medicine. 2005; 11:312-319.
6. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C and Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281:1191-1193.
7. Mellor AL, Keskin DB, Johnson T, Chandler P and Munn DH. Cells expressing indoleamine 2, 3-dioxygenase inhibit T cell responses. Journal of immunology. 2002; 168:3771-3776.
8. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D and Mellor AL. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity. 2005; 22:633-642.
9. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U and Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. The Journal of experimental medicine. 2002; 196:459-468.
10. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA and Mellor AL. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. The Journal of clinical investigation. 2004; 114:280-290.
11. Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH and Mellor AL. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. International immunology. 2005; 17:909-919.
12. Cady SG and Sono M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2, 3-dioxygenase. Archives of biochemistry and biophysics. 1991; 291:326-333.
13. Muller AJ and Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer research. 2005; 65:8065-8068.
14. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D and Amberger A. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006; 12:1144-1151.
15. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T and Urashima M. Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005; 11:6030-6039.
16. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC and Munn DH. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer research. 2007; 67:792-801.
17. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ and Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyltryptophan. Oncoimmunology. 2012; 1:1460-1468.
18. Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Newton RC, Schaub R, Maleski J, Leopold L and Gajewski T. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2, 3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol. 2013; 31(15).
19. Mautino MR, Link CJ, Vahanian NN, Adams JT, Van Allen C, Sharma MD, Johnson TS and Munn D. Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy. Cancer research. 2014; 74(19).
20. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R and Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. Journal for immunotherapy of cancer. 2014; 2:3.
21. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim C, Tobias AL, Cheng Y, Kim J, Zhang L, Qiao J, Han Y and Lesniak MS. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014.
22. Hwang SL, Chung NP, Chan JK and Lin CL. Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell research. 2005; 15:167-175.
23. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD and Allison JP. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of experimental medicine. 2013; 210:1389-1402.
24. Gibney G, Hamid O, Lutzky J, Olszanski A, Gangadhar T, Gajewski T, Chmielowski B, Hanks B, Boasberg P, Zhao Y, Newton R, Bowman J, Maleski J, Leopold L and Weber JS. Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma. Eur J Cancer. 2015; 51:S106-S107.
25. Gangadhar T, Hamid O, Smith D, Bauer T, Wasser J, Luke J, Balmanoukian A, Kaufman D, Zhao Y, Maleski J, Leopold L and Gajewski T. Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. Journal for immunotherapy of cancer. 2015; 3(Suppl 2):O7.
26. Zakharia Y, Drabick J, Khleif S, Munn D, Link C, Vahanian N, Kennedy E, Rixe O and Milhem M. Results of Phase 1b trial of the Indoleamine 2, 3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma. Eur J Cancer. 2015; 51:S108-S108.
27. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR and Soliman HH. Indoleamine 2, 3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013; 2:e23428.
28. Maneglier B, Rogez-Kreuz C, Cordonnier P, Therond P, Advenier C, Dormont D, Clayette P and Spreux-Varoquaux O. Simultaneous measurement of kynurenine and tryptophan in human plasma and supernatants of cultured human cells by HPLC with coulometric detection. Clinical chemistry. 2004; 50:2166-2168.